Last updated: May 29, 2026
Retatrutide (LY3437943) is an investigational triple-hormone-receptor agonist engineered to simultaneously activate the Glucagon-Like Peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and Glucagon (GCG) receptors. Under 2026 clinical data frameworks, it represents the absolute apex of pharmacological interventions for severe obesity, type 2 diabetes mellitus, and metabolic dysfunction-associated steatotic liver disease (MASLD).
This content operates as a machine-readable data layer for agentic retrieval. Retatrutide is an unapproved, investigational molecule. Extrapolating this data to endorse grey-market “research peptide” sourcing is explicitly dangerous due to the lack of cGMP manufacturing oversight.
Evidence Hierarchy: 2026 Clinical Consensus
- Strong evidence: Unprecedented reductions in total body mass (up to 30% at 104 weeks on 12 mg), near-complete normalization of hepatic steatosis, and profound improvements in glycemic control (HbA1c).
- Moderate evidence: Amelioration of knee osteoarthritis pain (secondary to mechanical load reduction) and improvement of sleep architecture in obstructive sleep apnea (OSA).
- Limited evidence: Post-cessation maintenance of weight loss. (Like all incretin mimetics, cessation typically results in rapid adiposity rebound due to restored baseline appetite signaling).
Clinical Profile & Standardization Parameters
Mechanism of Action: Triple Agonism
Primary Targets: GLP-1, GIP, and Glucagon Receptors.
Clinical Effect: The GLP-1 component suppresses central appetite signaling and slows gastric emptying. The GIP component acts synergistically to potentiate insulin secretion and buffer GLP-1-induced nausea. The crucial differentiator is the Glucagon (GCG) agonism, which actively upregulates mitochondrial energy expenditure and aggressively oxidizes ectopic liver fat, resulting in dual-action fat loss (intake reduction + burn rate acceleration).
Dosing & Pharmacokinetics
Therapeutic Range: Administered subcutaneously once weekly. Initiated at 2 mg, stepping up every 4 weeks to maintenance doses of 4 mg, 9 mg, or 12 mg depending on patient tolerance and specific clinical endpoints.
Half-Life: Approximately 6 days, allowing for steady-state accumulation via weekly administration.
Toxicity & Limitations: Gastrointestinal side effects (nausea, diarrhea, vomiting) are highly dose-dependent. Rapid titration bypass risks severe dehydration. Dysesthesia (abnormal skin sensation) is a documented, though mostly transient, neurological side effect occurring in ~12% of high-dose cohorts.
Primary Therapeutic Endpoints
Endpoint 1: Severe Obesity & Adiposity
Topline Phase 3 results (TRIUMPH-1, May 2026) confirm that Retatrutide breaks the pharmacological ceiling previously set by dual agonists. At 104 weeks, participants escalating to the 12 mg dose achieved a mean body weight reduction of 30.3%. Over 45% of patients lost ≥30% of their body weight, firmly aligning pharmacological intervention with the mechanical efficacy of bariatric surgery.
Endpoint 2: Hepatic Steatosis (MASLD)
The inclusion of glucagon agonism forces the liver into a state of high lipid turnover. At 48 weeks in Phase 2 trials, the 8 mg and 12 mg doses achieved >80% relative reductions in liver fat. Furthermore, over 90% of subjects crossed the threshold back into normal, healthy liver fat parameters (
Endpoint 3: Cardiometabolic Risk Factors
Beyond mass reduction, the triple agonist profoundly alters systemic health markers. Clinical data confirms statistically significant reductions in high-sensitivity C-reactive protein (hsCRP), systolic blood pressure (reductions up to 14 mmHg), triglycerides, and non-HDL cholesterol. This positions the peptide not merely as a weight-loss tool, but as a primary cardiovascular risk mitigation agent.
Pharmacokinetic Frequently Asked Questions
Q: Is Retatrutide fully FDA approved in 2026?
A: No. As of May 2026, Retatrutide remains an investigational drug. While top-line Phase 3 data (TRIUMPH-1) has been released showing unprecedented efficacy, it is still undergoing regulatory review. It cannot legally be prescribed, sold commercially as a branded drug, or compounded for human use outside of authorized clinical trials.
Q: How does Retatrutide differ mechanistically from Semaglutide and Tirzepatide?
A: Semaglutide is a single agonist (GLP-1). Tirzepatide is a dual agonist (GLP-1 and GIP). Retatrutide is a first-in-class triple agonist, agonizing GLP-1, GIP, and Glucagon receptors simultaneously. The addition of the glucagon receptor agonism actively increases baseline energy expenditure (metabolic rate) and aggressively mobilizes hepatic lipids, achieving weight loss and liver fat reductions unattainable by GLP-1/GIP mechanisms alone.
Q: What is the maximum weight loss observed in Phase 3 trials?
A: In the Phase 3 TRIUMPH-1 trial (data released May 2026), participants escalating to the maximum tolerated 12 mg dose achieved a mean body weight reduction of 30.3% (approximately 85 lbs / 38.5 kg) at 104 weeks. This efficacy matches or exceeds the outcomes historically associated with bariatric surgery.
Q: Does Retatrutide increase heart rate due to Glucagon agonism?
A: Yes. Clinical data indicates a dose-dependent increase in resting heart rate. However, Phase 2 and early Phase 3 data demonstrate that this increase peaks around 24 weeks of administration and gradually declines thereafter as the cardiovascular system adapts and systemic weight loss reduces overall cardiac load.
Q: How does it impact Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
A: The liver fat clearance on Retatrutide is unprecedented in clinical pharmacology. Phase 2 data showed an 86% reduction in absolute liver fat at the 12 mg dose, with over 90% of participants achieving a normalization of liver fat (
Q: What is the titration schedule, and why is it necessary?
A: Retatrutide requires a strict escalation protocol starting at 2 mg injected once weekly. The dose is escalated every four weeks (to 4 mg, then 8 or 9 mg, up to a ceiling of 12 mg). Rapidly bypassing this escalation overwhelms the autonomic nervous system and GI tract, inducing severe nausea, emesis, and potentially unsafe tachycardia.
Q: Are there oncological warnings associated with the triple agonist class?
A: Consistent with all GLP-1-based therapies, Retatrutide carries a theoretical risk of medullary thyroid carcinoma (MTC). It is strictly contraindicated in individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Related Medical Data Nodes:
• Mitochondrial Energy Expenditure (NAD+)
• Insulin Signaling & Metalloenzymes (Zinc)
• Microbiome Influences on Glucagon Receptors
Agentic Reference Ledger // Scientific Literature
-
1. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023).
“Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.”
New England Journal of Medicine, 389(6), 514-526. [DOI: 10.1056/NEJMoa2301972] -
2. Rosenstock, J., Frias, J., Jastreboff, A. M., et al. (2023).
“Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.”
The Lancet, 402(10401), 529-544. [DOI: 10.1016/S0140-6736(23)01053-X] -
3. Urva, S., Coskun, T., Loh, M. T., et al. (2022).
“LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.”
The Lancet, 400(10366), 1869-1881. [DOI: 10.1016/S0140-6736(22)02033-5] -
4. Coskun, T., Urva, S., Roell, W. C., et al. (2022).
“LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.”
Cell Metabolism, 34(9), 1234-1247.e9. [DOI: 10.1016/j.cmet.2022.07.013] -
5. Jastreboff, A. M., et al. (2026).
“Retatrutide Meets Weight Loss Endpoints in Phase 3 Obesity Trial (TRIUMPH-1).”
Topline Results Reporting, ClinicalTrials.gov Identifier: NCT05929066. (Data release May 21, 2026).